simvastatin has been researched along with Malignant Melanoma in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA | 1 |
| Bagasariya, D; Bala Singh, S; Charan Kumar, K; Famta, P; Fernandes, V; Kumar Khatri, D; Sabiya Samim, K; Shah, S; Srivastava, S | 1 |
| Chodurek, E; Pilawa, B; Zdybel, M | 1 |
| Baba, K; Kambayashi, S; Kobayashi, K; Okuda, M | 1 |
| Duan, X; Huang, J; Huang, Y; Lai, Y; Long, H; Wu, W; Zhang, S; Zhang, Y | 1 |
| Barone, A; Cabral, C; Mare, R; Mendes, M; Paolino, D; Vitorino, C | 1 |
| Li, YX; Wang, Y; Wu, YZ; Xu, SL; Xu, WJ; Yang, HY; Zhao, MS | 1 |
| Guterres, FA; Martinez, GR; Rocha, ME; Winnischofer, SM | 1 |
| Hohenegger, M; Höller, C; Künzl, M; Minichsdorfer, C; Wasinger, C; Zellner, M | 1 |
| Atil, B; Hohenegger, M; Minichsdorfer, C; Sieczkowski, E; Wasinger, C | 1 |
| Hohenegger, M; Minichsdorfer, C | 1 |
| Barros, FE; Bohatch, MS; Borelli, P; Bydlowski, SP; F Otuki, M; Favero, GM; Fernandes, D; Maria, DA; Oliveira, KA | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Clynes, M; Eustace, AJ; Glynn, SA; O'Donovan, N; O'Sullivan, D | 1 |
| Furukawa, H; Mol, W; Oyama, A; Saito, A; Saito, N; Sasaki, S; Sekido, M; Tsutsumida, A; Yamamoto, Y | 1 |
1 review(s) available for simvastatin and Malignant Melanoma
| Article | Year |
|---|---|
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
14 other study(ies) available for simvastatin and Malignant Melanoma
| Article | Year |
|---|---|
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones | 2021 |
Quality by design (QbD) assisted Fabrication & evaluation of Simvastatin loaded Nano-Enabled thermogel for melanoma therapy.
Topics: Humans; Melanoma; Nanoparticles; Simvastatin; Tumor Microenvironment | 2022 |
Application of EPR spectroscopy to determine the influence of simvastatin concentration on free radicals in A-375 human melanoma malignum cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; Free Radicals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma; Simvastatin; Skin Neoplasms | 2019 |
Effect of simvastatin on cell proliferation and Ras activation in canine tumour cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphoma; Melanoma; ras Proteins; Simvastatin | 2021 |
Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Topics: Abietanes; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Poly (ADP-Ribose) Polymerase-1; Simvastatin; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Hybrid Nanostructured Films for Topical Administration of Simvastatin as Coadjuvant Treatment of Melanoma.
Topics: Adhesives; Administration, Topical; Animals; Cell Line; Chitosan; Chlorocebus aethiops; COS Cells; Drug Carriers; Drug Liberation; Humans; Lipids; Melanoma; Melanoma, Cutaneous Malignant; Nanoparticles; Nanostructures; Particle Size; Permeability; Simvastatin; Skin; Skin Absorption; Skin Neoplasms | 2019 |
Simvastatin induces caspase-dependent apoptosis and activates P53 in OCM-1 cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cell Proliferation; Cell Survival; Choroid Neoplasms; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; G1 Phase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma; Mitochondria; Oncogene Proteins; Reactive Oxygen Species; Simvastatin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Humans; Melanoma; Reactive Oxygen Species; Signal Transduction; Simvastatin; Tumor Suppressor Protein p53 | 2013 |
Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.
Topics: Apoptosis; Autocrine Communication; Caspase 8; Cell Line, Tumor; Cells, Cultured; Fatty Acid-Binding Proteins; Gene Knockdown Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Lipocalins; Melanocytes; Melanoma; Neoplasm Metastasis; Prostaglandin D2; Simvastatin | 2014 |
Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-X Protein; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Melanoma; Neoplasm Metastasis; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Skin Neoplasms; STAT3 Transcription Factor; Wound Healing | 2015 |
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autocrine Communication; Biological Factors; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Pyridines; Pyrroles; Simvastatin; Time Factors | 2009 |
Simvastatin impairs murine melanoma growth.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Flow Cytometry; Liver; Male; Melanoma; Mice; Mice, Inbred C57BL; Simvastatin; Spleen | 2010 |
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lung Neoplasms; Male; Melanoma; Neoplasm Invasiveness; Simvastatin; Skin Neoplasms | 2008 |
Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma; Polyisoprenyl Phosphates; RNA, Messenger; Sesquiterpenes; Simvastatin | 2008 |